NCT07260370 The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy
| NCT ID | NCT07260370 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chang Gung Memorial Hospital |
| Condition | microRNA |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2018-05-23 |
| Primary Completion | 2025-12-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2018-05-23 with a primary completion date of 2025-12-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Among the currently important biomarkers, circulating tumor cells and microRNA (miRNA) have received significant attention. The latter, also translated as micro-ribonucleic acid, is a widely present ribonucleic acid (RNA) molecule in eukaryotes, approximately 21 to 23 nucleotides in length, which regulates the expression of other genes. miRNAs originate from RNAs that are transcribed from DNA but cannot be further translated into proteins (classified as non-coding RNA). miRNAs bind to target messenger RNA (mRNA), thereby inhibiting post-transcriptional gene expression, and play important roles in regulating gene expression, the cell cycle, and the timing of biological development.The project will recruit 300 subjects who have been diagnosed with cancer by a physician and for whom the decision has been made to use immunotherapy. Blood samples will be collected before and after treatment (past pathological diagnostic tissues may also be reviewed as required for the study). The study will analyze the differences in the quantity of free microRNAs, the number of circulating tumor cells, and the differences in surface antigen expression in the subjects' blood, as well as the specific surface antigen expression status in the cancer tissues, and perform statistical analysis.
Eligibility Criteria
Inclusion Criteria: 1. Aged above 20 years. 2. A patient diagnosed with cancer with immunotherapy 3. Competent to give informed consent and agree to join the study. Exclusion Criteria: 1. Aged \< 20 years. 2. Refuse to join the study
Contact & Investigator
Chia-Hsun Hsieh, PhD
PRINCIPAL INVESTIGATOR
Division of Oncology, Chang Gung Memorial Hospital
Frequently Asked Questions
Who can join the NCT07260370 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying microRNA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07260370 currently recruiting?
Yes, NCT07260370 is actively recruiting participants. Contact the research team at wisdom5000@gmail.com for enrollment information.
Where is the NCT07260370 trial being conducted?
This trial is being conducted at Taoyuan City, Taiwan.
Who is sponsoring the NCT07260370 clinical trial?
NCT07260370 is sponsored by Chang Gung Memorial Hospital. The principal investigator is Chia-Hsun Hsieh, PhD at Division of Oncology, Chang Gung Memorial Hospital. The trial plans to enroll 300 participants.